Brokerages predict that Intrexon Corp (NYSE:XON) will report sales of $55.29 million for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Intrexon’s earnings. The lowest sales estimate is $52.75 million and the highest is $58.70 million. Intrexon reported sales of $53.75 million in the same quarter last year, which indicates a positive year-over-year growth rate of 2.9%. The business is scheduled to announce its next earnings report on Wednesday, May 9th.
According to Zacks, analysts expect that Intrexon will report full-year sales of $55.29 million for the current financial year, with estimates ranging from $210.00 million to $271.42 million. For the next fiscal year, analysts forecast that the firm will report sales of $285.23 million per share, with estimates ranging from $244.08 million to $346.50 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Intrexon.
Intrexon (NYSE:XON) last posted its earnings results on Thursday, March 1st. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.08. Intrexon had a negative net margin of 50.61% and a negative return on equity of 16.94%. The firm had revenue of $77.03 million during the quarter, compared to analysts’ expectations of $48.16 million. During the same period in the previous year, the business posted ($0.37) EPS. The business’s revenue was up 67.5% compared to the same quarter last year.
Intrexon (NYSE:XON) opened at $16.78 on Thursday. The company has a quick ratio of 1.67, a current ratio of 1.92 and a debt-to-equity ratio of 0.01. Intrexon has a 12 month low of $10.26 and a 12 month high of $26.99. The stock has a market cap of $2,150.24, a price-to-earnings ratio of -17.12 and a beta of 1.30.
In related news, CEO Randal J. Kirk acquired 1,000,000 shares of Intrexon stock in a transaction on Friday, January 19th. The stock was bought at an average cost of $12.50 per share, for a total transaction of $12,500,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 55.10% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp raised its position in Intrexon by 1.4% during the third quarter. Bank of New York Mellon Corp now owns 237,373 shares of the biotechnology company’s stock worth $4,512,000 after acquiring an additional 3,234 shares during the period. Macquarie Group Ltd. raised its position in Intrexon by 11.8% during the fourth quarter. Macquarie Group Ltd. now owns 40,231 shares of the biotechnology company’s stock worth $463,000 after acquiring an additional 4,236 shares during the period. Raymond James Financial Services Advisors Inc. raised its position in Intrexon by 7.5% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 63,568 shares of the biotechnology company’s stock worth $1,208,000 after acquiring an additional 4,422 shares during the period. Teachers Advisors LLC raised its position in shares of Intrexon by 9.0% in the fourth quarter. Teachers Advisors LLC now owns 68,326 shares of the biotechnology company’s stock valued at $787,000 after buying an additional 5,623 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC raised its position in shares of Intrexon by 18.1% in the third quarter. Sheaff Brock Investment Advisors LLC now owns 40,452 shares of the biotechnology company’s stock valued at $769,000 after buying an additional 6,210 shares during the last quarter. Institutional investors own 76.08% of the company’s stock.
Intrexon Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.